Submitted:
13 October 2025
Posted:
14 October 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
1.1. Pathophysiology Overview
2. Methods
3. Epidemiology and Geographic Patterns
3.1. Global Incidence and Regional Variations
3.2. Demographic Characteristics and Ethnic Disparities
4. Clinical Presentation and Diagnostic Challenges
4.1. Incomplete Presentations and Atypical Features
4.2. Gastrointestinal Manifestations
4.3. Musculoskeletal Manifestations
4.4. Neurological and Other Manifestations
4.5. Laboratory and Imaging Findings
5. Cardiovascular Complications and Treatment Outcomes
5.1. Coronary Artery Involvement
5.2. Treatment Resistance and Advanced Therapies
7. Long-Term Outcomes and Prognosis
7.1. Cardiovascular Sequelae
7.2. Surveillance and Risk Factor Management
8. Transition to Adult Care
8.1. Challenges in Healthcare Transition
8.2. Structured Transition Programs
9. Limitations
10. Future Directions and Research Gaps
11. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
Abbreviations
| CAA = Coronary artery abnormalities |
| GI = Gastrointestinal |
| IVIG = Intravenous immunoglobulin |
| KD = Kawasaki disease |
| M:F = Male-to-female ratio |
| MIS-C = Multisystem Inflammatory Syndrome in Children |
| MSK = Musculoskeletal |
| NR = Not reported |
References
- McCrindle, B.W.; Rowley, A.H.; Newburger, J.W.; Burns, J.C.; Bolger, A.F.; Gewitz, M.; Baker, A.L.; Jackson, M.A.; Takahashi, M.; Shah, P.B.; et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017, 135, e927–e999. [CrossRef]
- Xiaoliang Liu; Liu, X.; Fang Wang; Wang, F.; Kaiyu Zhou; Zhou, K.; Hua, Y.; Yimin Hua; Hua, Y.; Mei Wu; et al. Clinical Characteristics of Kawasaki Disease in Adolescents. Journal of International Medical Research 2021, 49, 3000605211056839. [CrossRef]
- Holman, R.C.; Belay, E.D.; Christensen, K.Y.; Folkema, A.M.; Steiner, C.A.; Schonberger, L.B. Hospitalizations for Kawasaki Syndrome among Children in the United States, 1997-2007. Pediatr Infect Dis J 2010, 29, 483–488. [CrossRef]
- Jindal, A.K.; Pilania, R.K.; Guleria, S.; Vignesh, P.; Suri, D.; Gupta, A.; Singhal, M.; Rawat, A.; Singh, S. Kawasaki Disease in Children Older Than 10 Years: A Clinical Experience From Northwest India. Front Pediatr 2020, 8, 24. [CrossRef]
- Jone, P.-N.; Tremoulet, A.; Choueiter, N.; Dominguez, S.R.; Harahsheh, A.S.; Mitani, Y.; Zimmerman, M.; Lin, M.-T.; Friedman, K.G.; on behalf of the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Clinical Cardiology Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. Circulation 2024, 150, e481–e500. [CrossRef]
- Ae, R.; Makino, N.; Kosami, K.; Kuwabara, M.; Matsubara, Y.; Nakamura, Y. Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018. J Pediatr 2020, 225, 23-29.e2. [CrossRef]
- Feldstein, L.R.; Rose, E.B.; Horwitz, S.M.; Collins, J.P.; Newhams, M.M.; Son, M.B.F.; Newburger, J.W.; Kleinman, L.C.; Heidemann, S.M.; Martin, A.A.; et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 2020, 383, 334–346. [CrossRef]
- Hara, T.; Yamamura, K.; Sakai, Y. The Up-to-Date Pathophysiology of Kawasaki Disease. Clinical & Translational Immunology 2021, 10, e1284. [CrossRef]
- Vaňková, L.; Bufka, J.; Křížková, V. Pathophysiological and Clinical Point of View on Kawasaki Disease and MIS-C. Pediatrics & Neonatology 2023, 64, 495–504. [CrossRef]
- Falcini, F.; Cimaz, R.; Calabri, G.B.; Picco, P.; Martini, G.; Marazzi, M.G.; Simonini, G.; Zulian, F. Kawasaki’s Disease in Northern Italy: A Multicenter Retrospective Study of 250 Patients. Clin Exp Rheumatol 2002, 20, 421–426.
- Tremoulet, A.H.; Best, B.M.; Song, S.; Wang, S.; Corinaldesi, E.; Eichenfield, J.R.; Martin, D.D.; Newburger, J.W.; Burns, J.C. Resistance to Intravenous Immunoglobulin in Children with Kawasaki Disease. The Journal of Pediatrics 2008, 153, 117-121.e3. [CrossRef]
- Watanabe, Y.; Ikeda, H.; Watanabe, T. Differences in the Clinical Characteristics of Kawasaki Disease Between Older and Younger Children (2015-2019): A Single-Center, Retrospective Study. The Journal of Pediatrics 2023, 253, 266–269. [CrossRef]
- Liu, J.; Huang, Y.; Chen, C.; Su, D.; Qin, S.; Pang, Y. Risk Factors for Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Abnormalities in a Chinese Pediatric Population With Kawasaki Disease: A Retrospective Cohort Study. Front Pediatr 2022, 10, 812644. [CrossRef]
- Najib Advani; Advani, N.; Lucyana Alim Santoso; Santoso, L.A.; Sudigdo Sastroasmoro; Sastroasmoro, S. Profile of Kawasaki Disease in Adolescents: Is It Different? Acta medica Indonesiana 2019, 51, 42–46.
- Huang, Y.-H.; Lin, K.-M.; Ho, S.-C.; Yan, J.-H.; Lo, M.-H.; Kuo, H.-C. Increased Incidence of Kawasaki Disease in Taiwan in Recent Years: A 15 Years Nationwide Population-Based Cohort Study. Front Pediatr 2019, 7, 121. [CrossRef]
- Kim, G.B.; Eun, L.Y.; Han, J.W.; Kim, S.H.; Yoon, K.L.; Han, M.Y.; Yu, J.J.; Choi, J.-W.; Rhim, J.W. Epidemiology of Kawasaki Disease in South Korea: A Nationwide Survey 2015-2017. Pediatr Infect Dis J 2020, 39, 1012–1016. [CrossRef]
- Odingo, M.; Rutter, M.; Bowley, J.; Peach, E.J.; Lanyon, P.C.; Grainge, M.J.; Stillwell, P.; McPhail, S.; Bythell, M.; Aston, J.; et al. The Incidence of Kawasaki Disease Using Hospital Admissions Data for England 2006–2021. Rheumatology (Oxford) 2023, 62, 3117–3125. [CrossRef]
- Taslakian, E.N.; Wi, C.-I.; Seol, H.Y.; Boyce, T.G.; Johnson, J.N.; Ryu, E.; King, K.S.; Juhn, Y.J.; Choi, B.S. Long-Term Incidence of Kawasaki Disease in a North American Community: A Population-Based Study. Pediatr Cardiol 2021, 42, 1033–1040. [CrossRef]
- Holman, R.C.; Christensen, K.Y.; Belay, E.D.; Steiner, C.A.; Effler, P.V.; Miyamura, J.; Forbes, S.; Schonberger, L.B.; Melish, M. Racial/Ethnic Differences in the Incidence of Kawasaki Syndrome among Children in Hawaii. Hawaii Med J 2010, 69, 194–197.
- MacGillivray, D.M.; Kollmann, T.R. The Role of Environmental Factors in Modulating Immune Responses in Early Life. Front Immunol 2014, 5, 434. [CrossRef]
- Sato, M.; Fujita, Y.; Naganuma, J.; Sekine, K.; Watanabe, S.; Ogino, K.; Suzuki, K.; Yoshihara, S. Kawasaki Disease Preceded by Acute Appendicitis Treated with Intravenous Immunoglobulin without Surgery. Rheumatol Advanc Pract 2025, 9, rkaf003. [CrossRef]
- Burns, J.C.; Roberts, S.C.; Tremoulet, A.H.; He, F.; Printz, B.F.; Ashouri, N.; Jain, S.S.; Michalik, D.E.; Sharma, K.; Truong, D.T.; et al. Infliximab versus Second Intravenous Immunoglobulin for Treatment of Resistant Kawasaki Disease in the USA (KIDCARE): A Randomised, Multicentre Comparative Effectiveness Trial. Lancet Child Adolesc Health 2021, 5, 852–861. [CrossRef]
- Kim, B.Y.; Kim, D.; Kim, Y.H.; Ryoo, E.; Sun, Y.H.; Jeon, I.-S.; Jung, M.-J.; Cho, H.K.; Tchah, H.; Choi, D.Y.; et al. Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children. Korean Circ J 2016, 46, 542–549. [CrossRef]
- Chen, D.T.-L.; Chang, J.P.-C.; Cheng, S.-W.; Chang, H.-C.; Hsu, J.-H.; Chang, H.-H.; Chiu, W.-C.; Su, K.-P. Kawasaki Disease in Childhood and Psychiatric Disorders: A Population-Based Case-Control Prospective Study in Taiwan. Brain, Behavior, and Immunity 2022, 100, 105–111. [CrossRef]
- Robinson, C.; Chanchlani, R.; Gayowsky, A.; Darling, E.; Seow, H.; Batthish, M. Health Care Utilization and Costs Following Kawasaki Disease. Paediatr Child Health 2022, 27, 160–168. [CrossRef]
- Chen, D.T.-L.; Chang, J.P.-C.; Cheng, S.-W.; Chang, H.-C.; Hsu, J.-H.; Chang, H.-H.; Chiu, W.-C.; Su, K.-P. Kawasaki Disease in Childhood and Psychiatric Disorders: A Population-Based Case-Control Prospective Study in Taiwan. Brain, Behavior, and Immunity 2022, 100, 105–111. [CrossRef]
- Manlhiot, C.; Millar, K.; Golding, F.; McCrindle, B.W. Improved Classification of Coronary Artery Abnormalities Based Only on Coronary Artery Z-Scores after Kawasaki Disease. Pediatr Cardiol 2010, 31, 242–249. [CrossRef]
- Tsuda, E.; Abe, T.; Tamaki, W. Acute Coronary Syndrome in Adult Patients with Coronary Artery Lesions Caused by Kawasaki Disease: Review of Case Reports. Cardiol Young 2011, 21, 74–82. [CrossRef]
- Gorelik, M.; Chung, S.A.; Ardalan, K.; Binstadt, B.A.; Friedman, K.; Hayward, K.; Imundo, L.F.; Lapidus, S.K.; Kim, S.; Son, M.B.; et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care Res (Hoboken) 2022, 74, 538–548. [CrossRef]


| Study (Country, Year) | Design | Sample Size | Age (M:F) | Coronary Involvement/IVIG Resistance (%) | Key Findings |
|---|---|---|---|---|---|
| Jindal et al. [4] (India, 2020) |
Retrospective cohort | 45 | 10-16y (1.3:1) | 73%/31% | Delayed diagnosis; incomplete criteria |
| Liu et al. [2] (Japan, 2021) |
Cross-sectional | 89 | 10-17y (1.2:1) | 67%/28% | Atypical symptoms; diagnostic delays |
| Holman et al. [3] (USA, 2010) |
Population-based | 173/2162 | 10-17y (1.4:1) | NR/↑ vs younger | 8% of all KD; higher complications |
| Ae et al.[6] (Japan, 2020) |
National registry | 1234 | 10-19y (1.5:1) | NR/32% | 6.2% of national KD cases |
| Falcini et al. [10] (Italy, 2002) |
Multicenter retrospective | 38/250 | 10-16y (1.4:1) | 63%/42% | Incomplete criteria; 2-3d delay |
| Tremoulet et al. [11] (USA, 2008) | Clinical trial subanalysis | 67/362 | 9-17y (1.2:1) | NR/35% | Higher IVIG resistance; longer hospitalization |
| Watanabe et al. [12] (Japan, 2023) | Single-center retrospective | 34 | 10-15y (1.1:1) | 62%/30% | Abdominal/musculoskeletal symptoms |
| Jie Liu et al. [13] (China, 2022) |
Retrospective cohort | 52 | 11-17y (1.3:1) | 68%/29% | GI and neurological symptoms |
| Advani et al. [14] (Indonesia, 2019) |
Cross-sectional | 17/1150 | 10-18y (M>F) | 47%/NR | 59% incomplete KD |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).